Related Experiment Video
Updated: Nov 15, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Management of Central Retinal Artery Occlusion: A Scientific Statement From the American Heart Association
Insights
Central retinal artery occlusion (CRAO) is an emergency requiring prompt care. Intravenous tissue plasminogen activator may be effective, but more research is needed for optimal CRAO management and secondary prevention.
Area of Science:
- Ophthalmology
- Neurology
- Cardiology
Background:
- Central retinal artery occlusion (CRAO) is an acute ischemic stroke with severe vision loss.
- It signals increased risk for cerebrovascular and cardiovascular events.
- Current CRAO management relies heavily on limited observational data and expert consensus.
Purpose of the Study:
- To critically appraise existing literature on CRAO management.
- To establish a framework for acute treatment and secondary prevention strategies.
- To address the paucity of scientific information regarding CRAO.
Main Methods:
- Comprehensive literature review including RCTs, cohort studies, case reports, and guidelines.
- Expert panel formation with specialists in neurology, ophthalmology, cardiology, and related fields.
- Systematic data synthesis and consensus development through multiple draft revisions.
Main Results:
- Acute CRAO necessitates immediate medical attention and efficient triage systems.
- Intravenous tissue plasminogen activator shows potential efficacy in acute CRAO treatment.
- Urgent screening and management of vascular risk factors are crucial for patients.
Conclusions:
- Standardized systems of care are needed for rapid CRAO recognition and treatment.
- Further high-quality randomized clinical trials are essential to guide CRAO management.
- Addressing vascular risk factors is critical for secondary prevention in CRAO patients.
Purpose:
Central retinal artery occlusion (CRAO) is a form of acute ischemic stroke that causes severe visual loss and is a harbinger of further cerebrovascular and cardiovascular events. There is a paucity of scientific information on the appropriate management of CRAO, with most strategies based on observational literature and expert opinion. In this scientific statement, we critically appraise the literature on CRAO and provide a framework within which to consider acute treatment and secondary prevention.
Methods:
We performed a literature review of randomized controlled clinical trials, prospective and retrospective cohort studies, case-control studies, case reports, clinical guidelines, review articles, basic science articles, and editorials concerning the management of CRAO. We assembled a panel comprising experts in the fields of vascular neurology, neuro-ophthalmology, vitreo-retinal surgery, immunology, endovascular neurosurgery, and cardiology, and document sections were divided among the writing group members. Each member received an assignment to perform a literature review, synthesize the data, and offer considerations for practice. Multiple drafts were circulated among the group until consensus was achieved.
Results:
Acute CRAO is a medical emergency. Systems of care should evolve to prioritize early recognition and triage of CRAO to emergency medical attention. There is considerable variability in management patterns among practitioners, institutions, and subspecialty groups. The current literature suggests that treatment with intravenous tissue plasminogen activator may be effective. Patients should undergo urgent screening and treatment of vascular risk factors. There is a need for high-quality, randomized clinical trials in this field.
